Investing.com - H.C. Wainwright在Compass Pathways(纳斯达克股票代码:CMPS)公布2025年第四季度及全年业绩后,重申了买入评级和70美元的目标价。 该公司指出,Compass Pathways于3月24日公布的业绩概述了一条监管路径,可能在2026年第四季度提交滚动新药申请。该公司还提出了一个利用现有介入精神病学基础设施的商业模式框架。 Compa ...

在其他近期发展中,Compass ...

Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways ...

Compass Pathways (NASDAQ:CMPS) executives outlined plans for a potential U.S. regulatory filing and commercial launch ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported the fourth quarter and full-year ...

LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today ...

The average one-year price target for COMPASS Pathways plc - Depositary Receipt (NasdaqGS:CMPS) has been revised to $23.77 / ...

LONDON, April 29, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, and ...

LONDON, Aug. 16, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced ...

Participants received a single dose of either 25 mg of COMP360 or placebo On track for disclosure of top-line 6-week primary endpoint results in late June To date, the COMP005 trial is the largest, ...

LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it is entering ...

LONDON, April 29, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental ...